The Peptide Directory

Not approved (research only)Growth hormone secretagogue (ghrelin-receptor agonist)Growth hormone

Ipamorelin

Not FDA-approved.

Last reviewed by The Peptide Directory Editorial Team

What is Ipamorelin?

Ipamorelin is a synthetic five-amino-acid peptide that stimulates growth-hormone release through the ghrelin receptor; it was described in 1998 as the first selective growth hormone secretagogue and is not FDA-approved.

Key takeaways

  1. Selective: in the original animal work it raised GH without large rises in ACTH or cortisol.
  2. Not approved for any human use.
  3. Commonly paired with CJC-1295 by clinics; that combination has no approval either.

Structure

2D chemical structure of Ipamorelin (C38H49N9O5), as depicted by PubChem
Structure: PubChem CID 9831659 (C38H49N9O5, 711.9 g/mol). 2D depiction from NCBI PubChem, retrieved October 19, 2026.

What makes Ipamorelin different?

Its selling point in the 1998 paper was selectivity — GH release without the cortisol and prolactin effects seen with earlier secretagogues.

How does Ipamorelin work?

Binds the growth hormone secretagogue receptor (ghrelin receptor) in the pituitary, triggering pulsatile GH release.

What the clinical evidence actually shows

  • Raun et al., Eur J Endocrinol 1998: characterization in animal models.
  • No large human efficacy trials for body composition or anti-aging uses were identified.

How much research exists on Ipamorelin?

PubMed indexes 51 papers mentioning Ipamorelin in the title or abstract, 12 of them from the last five years and 2 tagged as clinical trials (search run October 19, 2026; repeat the search).

Most relevant recent papers

Registered clinical studies

ClinicalTrials.gov lists 3 studies with Ipamorelin as an intervention (see all). Most recent:

Side effects

Controlled human safety data are limited. GH-axis stimulation in general can affect glucose metabolism and fluid retention.

Regulatory & access status

  • Not FDA-approved.

Sourcing & safety

Sold online as a research chemical; some clinics prescribe compounded versions.

Doses in labels and trials

Reference only — copied from published research. Not a recommendation.

SourceWhat it says
Human doseNo established or approved human dose exists.

What the evidence does not show

  • Long-term benefit for muscle, fat loss or sleep in controlled human trials.
  • Long-term safety.

Ipamorelin FAQ

Is ipamorelin FDA-approved?

No. Ipamorelin is not approved for any use in humans.

How does ipamorelin work?

It activates the ghrelin (GH secretagogue) receptor, prompting the pituitary to release growth hormone.

Related peptides & comparisons

SermorelinTesamorelin Growth Hormone

References

  1. Ipamorelin, the first selective growth hormone secretagogue, Eur J Endocrinol (1998), PMID 9849822
  2. Ipamorelin — PubChem compound summary (CID 9831659), PubChem

Ipamorelin calculators

Lab arithmetic only: convert a mass to a volume or syringe units at a known concentration with the units converter, or work out a concentration with the reconstitution calculator.

There is no FDA-approved Ipamorelin product. Compounded versions depend on FDA's compounding rules, and "research use only" products are not for human use.

Get Ipamorelin via telehealth

None of the telehealth providers we have verified lists Ipamorelin.

Research suppliers that list Ipamorelin

41 vendors in our directory listed a product matching Ipamorelin in their public catalog on October 19, 2026. Listed alphabetically; a listing is not an endorsement. Research use only.

Prices per mg, where we could verify them, are on our price comparison.

Ipamorelin dosing protocol

There is no FDA-label or published-trial dosing schedule we can reproduce for Ipamorelin, so we don't publish one.

Find clinics offering Ipamorelin

49 verified clinics name Ipamorelin; browse them by state.

Browse all clinics